Andrew Cleeland

Andrew is a seasoned executive with over 30 years of experience in the medical device industry in both the private and public sectors. Mr. Cleeland is currently CEO of the Fogarty Institute for Innovation, a leading US non-profit incubator helping early-stage companies transform ideas into medical products that improve care.

Prior to joining the Fogarty Institute, he was Vice President and General Manager of Medtronic’s (MDT:NYSE) Transcatheter Mitral Valve business following its 2015 acquisition of Twelve Inc., where he was President and CEO. Prior to Twelve, he was President and CEO of Ardian Inc., the pioneer of renal denervation for hypertension, heart failure and other associated disorders, which was also acquired by Medtronic in 2011. Together these two acquisitions totaled $1.5B.

Andrew began his career with the Australian Therapeutic Goods Administration, progressed to large med tech companies in Telectronics Pacing Systems and Baxter Healthcare (BAX:NYSE), then onto the Silicon Valley start-up space working with Radiant Medical, Ardian and Twelve.

He is currently Vice Chairman of The Foundry, the premier medical device incubator based in Menlo Park, California and serves as a Director on the Boards of two venture-funded companies; Saluda Medical and Zenflow, Inc. (Chairman of the Board). He was also a Director at nVision Medical that was recently acquired by Boston Scientific (BSX:NYSE).